23andMe Launches Personal Genome Service For Carrier Screening After Work With FDA
This article was originally published in The Gray Sheet
Two years of conversations with FDA have led 23andMe back to the health care market with the Oct. 21 launch of its new Personal Genome Service, focused on carrier screening tests. The firm says its close engagement with FDA has improved its customer communication and quality control.
You may also be interested in...
Formalizing an approach applied to oversight of 23AndMe's direct-to-consumer genetic health risk tests, US FDA Nov. 6 said it plans to allow DTC testing services to be exempted from pre-market review after each individual maker of such an offering comes to the agency for a one-time review to ensure it meets FDA requirements.
The Google-backed firm's carrier screening assay for a rare disease called Bloom syndrome is the first DTC genetic test to achieve sign off from FDA. More importantly, the marketing authority was awarded in a manner that could significantly streamline the path to market for future DTC carrier-screening assays.
The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.